Category: Medmonitor

83 posts found

Recalls Impacting Workers’ Comp

A previous gastrointestinal drug recall expands, while a new recall for an anxiety drug is issued.

Indicated for various gastrointestinal concerns, these recalls could impact certain workers’ comp patients.

NKTR-181 (loxicodegol) was to receive an approval decision by August 29th, but a reevaluation of opioid policy has resulted in a delay.

Nine generic versions of Lyrica (pregabalin) have been approved for the treatment of five different medical conditions.

Generic versions of Ultram (tramadol hydrochloride) tablets and Dyloject (diclofenac sodium) injections have been approved by the FDA.

Orphengesic Forte has received a decision date of August 14, 2019.

The life saving antidote for opioid overdose will soon be available in a consumer-friendly, generic nasal spray.

New changes to REMS safety programs will require stronger treatment documentation and oversight.

Phase 3 clinical trials for this non-opioid drug demonstrate significant reductions in pain for osteoarthritis and chronic low-back pain.

The FDA created special drug labels to clear a development hurdle and encourage manufacturers.

The opioid prodrug for acute pain will soon be available in both a stronger and weaker dose.

The reSET-O app uses cognitive behavioral therapy techniques to assist patients engaged in medication-assisted therapy for opioid dependence.

Five-to-ten times stronger than fentanyl, this drug is not for consumer use, and many claim it could worsen the opioid crisis.

The marijuana-derived seizure drug now sits at schedule V, facing far fewer prescribing and dispensing restrictions.

Cassipa (buprenorphine and naloxone) sublingual film delivers a new dosage for the treatment of opioid dependence.

Prev 1 2 3 4 5 6 Next